Director at Jazz Pharmaceuticals (JAZZ) sells 6,000 company shares

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares of the company in open-market transactions. The sales occurred on 2026-04-01 at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. According to a footnote, these trades were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was not discretionary. After the transactions, Cozadd directly owned 384,682 ordinary shares of Jazz Pharmaceuticals.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares ($1,143,010)

Net Sell 3 txns

Insider COZADD BRUCE C

Role Director

Sold 6,000 shs ($1.14M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,684	$190.222	$701K
Sale	Ordinary Shares	2,292	$190.9383	$438K
Sale	Ordinary Shares	24	$191.7447	$5K

Holdings After Transaction: Ordinary Shares — 386,998 shares (Direct)

Footnotes (1)

This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.60 to $190.5603. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.6051 to $190.5982. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Key Figures

Shares sold: 6,000 ordinary shares Sale price tranche 1: $190.2220 per share Sale price tranche 2: $190.9383 per share +3 more

6 metrics

Shares sold 6,000 ordinary shares Total net shares sold on 1 April 2026

Sale price tranche 1 $190.2220 per share Weighted average price for 3,684 shares sold

Sale price tranche 2 $190.9383 per share Weighted average price for 2,292 shares sold

Sale price tranche 3 $191.7447 per share Weighted average price for 24 shares sold

Shares held after trades 384,682 ordinary shares Direct ownership after 1 April 2026 sales

Intermediate holdings 386,998 ordinary shares Direct ownership after first 3,684-share sale

Key Terms

Rule 10b5-1, weighted average sale price, open-market sale, ordinary shares, +1 more

5 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sale price financial

"The price reported reflects the weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ordinary shares financial

"Reflects sales of ordinary shares executed in multiple transactions"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 05:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/01/2026		S⁽¹⁾		3,684	D	$190.222⁽²⁾	386,998	D
Ordinary Shares	04/01/2026		S⁽¹⁾		2,292	D	$190.9383⁽³⁾	384,706	D
Ordinary Shares	04/01/2026		S⁽¹⁾		24	D	$191.7447	384,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.60 to $190.5603. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.6051 to $190.5982. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) disclose?

Jazz Pharmaceuticals reported that director Bruce C. Cozadd sold 6,000 ordinary shares in open-market transactions. These trades were executed on 1 April 2026 at weighted average prices around $190–$192 per share, and were made under a pre-arranged Rule 10b5-1 trading plan.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce Cozadd still hold?

After the reported sales, Bruce C. Cozadd directly holds 384,682 ordinary shares of Jazz Pharmaceuticals. This post-transaction figure reflects his remaining direct ownership following multiple open-market sales totaling 6,000 shares executed on 1 April 2026.

At what prices were the Jazz Pharmaceuticals (JAZZ) shares sold?

The reported sales occurred at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. Footnotes explain these were averages for multiple trades within price ranges near those levels, with full trade-by-trade details available on request to regulators or security holders.

Was the Jazz Pharmaceuticals (JAZZ) insider sale pre-planned?

Yes. A footnote states the transactions were made under a Rule 10b5-1 trading plan adopted on 26 November 2025. This means the sales were scheduled in advance and executed automatically, rather than reflecting a discretionary timing decision by Bruce C. Cozadd.

Who is the reporting person in the Jazz Pharmaceuticals (JAZZ) Form 4?

The reporting person is Bruce C. Cozadd, identified as a director of Jazz Pharmaceuticals plc. The Form 4 shows his direct ownership of ordinary shares and details three open-market sale transactions executed on 1 April 2026 under a pre-arranged trading plan.